Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Antonio Vena, Nadia Castaldo, Laura Magnasco, Martina Bavastro, Alessandro Limongelli, Daniele Roberto Giacobbe & Matteo Bassetti. (2023) Current and emerging drug treatment strategies to tackle invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) infection: what are the challenges?. Expert Opinion on Pharmacotherapy 24:3, pages 331-346.
Read now
Read now
Matteo Bassetti, Monica Melchio & Daniele Roberto Giacobbe. (2022) Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Review of Anti-infective Therapy 20:5, pages 649-656.
Read now
Read now
Matteo Bassetti, Filippo Del Puente, Laura Magnasco & Daniele Roberto Giacobbe. (2020) Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opinion on Investigational Drugs 29:5, pages 495-506.
Read now
Read now
Matteo Bassetti, Maddalena Peghin, Nadia Castaldo & Daniele Roberto Giacobbe. (2019) The safety of treatment options for acute bacterial skin and skin structure
infections. Expert Opinion on Drug Safety 18:8, pages 635-650.
Read now
Read now
Articles from other publishers (8)
Adrien Turban, François Guérin, Aurélien Dinh & Vincent Cattoir. (2023) Updated Review on Clinically-Relevant Properties of Delafloxacin. Antibiotics 12:8, pages 1241.
Crossref
Crossref
Gregory J. Moran, Surya Chitra & Paul C. McGovern. (2022) Efficacy and Safety of Omadacycline Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections in Persons Who Inject Drugs. Infectious Diseases and Therapy 11:1, pages 517-531.
Crossref
Crossref
Barbara A. Brown Elliott & Richard J. WallaceJr.Jr.. (2021)
Comparison of
In Vitro
Susceptibility of Delafloxacin with Ciprofloxacin, Moxifloxacin, and Other Comparator Antimicrobials against Isolates of Nontuberculous Mycobacteria
. Antimicrobial Agents and Chemotherapy 65:7.
Crossref
Crossref
Matteo Bassetti, Laura Magnasco, Filippo Del Puente & Daniele Roberto Giacobbe. (2020) Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. Current Opinion in Infectious Diseases 33:2, pages 110-120.
Crossref
Crossref
SyedBilal Tanvir, SyedSaad Bin Qasim, Joe Latimer, Zeeshan Qamar & FayezHussain Niazi. (2020) The efficacy and adverse events of delafloxacin for treating acute bacterial skin and skin structure infections: A systematic review and meta-analysis. Journal of Pharmacy And Bioallied Sciences 12:5, pages 538.
Crossref
Crossref
Marcus R. Pereira & Meenakshi M. Rana. (2019)
Methicillin‐resistant
Staphylococcus aureus
in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
. Clinical Transplantation 33:9.
Crossref
Crossref
Paul M Tulkens, Françoise Van Bambeke & Stephen H Zinner. (2019) Profile of a Novel Anionic Fluoroquinolone—Delafloxacin. Clinical Infectious Diseases 68:Supplement_3, pages S213-S222.
Crossref
Crossref
忠秋 郭. (2019) Delafloxacin: A Novel Fluoroquinolones Broad-Spectrum Antibacterial. Pharmacy Information 08:01, pages 9-15.
Crossref
Crossref